The BCL2 antagonist ABT‐199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity in CXCR4Wild‐type and CXCR4WHIM mutated Waldenstrom macroglobulinaemia cells

Advani, R.H. , Buggy, J.J., Sharman, J.P., Smith, S.M. , Boyd, T.E. , Grant, B. , Kolibaba, K.S. , Furman, R.R. , Rodriguez, S. , Chang, B.Y. , Sukbuntherng, J., Izumi, R. , Hamdy, A. , Hedrick, E. & Fowler, N.H. (2013) Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. Journal of Clinical Oncology, 31, 88–94. Burger, J.A. & Buggy, J.J. (2013) Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765). Leukemia & Lymphoma, 54, 2385–2391. Byrd, J.C. , Furman, R.R. , Coutre, S.E. , Flinn, I.W. , Burger, J.A. , Blum, K.A. , Grant, B. , Sharman, J.P., Coleman, M. , Wierda, W.G. , Jones, J.A. , Zhao, W. , Heerema, N.A. , Johnson, A.J., Sukbuntherng, J., Chang, B.Y. , Clow, F. , Hedrick, E. , Buggy, J.J., James, D.F. & O’Brien, S. (2013) Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. New England Journal of Medicine, 369, 32–42. Chang, B.Y. , Francesco, M. , De Rooij, M.F. , Magadala, P., Steggerda, S.M. , Huang, M.M. , Kuil, A. , Herman, S.E. , Chang, S. , Pals, S.T. , Wilson, W. , Wiestner, A. , Spaargaren, M. , Buggy, J.J. & Elias, L. (2013) Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients. Blood, 122, 2412–2424. Cheson, B.D. , Byrd, J.C. , Rai, K.R. , Kay, N.E. , O’Brien, S.M. , Flinn, I.W. , Wiestner, A. & Kipps, T.J. (2012) Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia. Journal of Clinical Oncology, 30, 2820–2822. Cinar, M. , Hamedani, F. , Mo, Z. , Cinar, B. , Amin, H.M. & Alkan, S. (2013) Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by Ibrutinib induces apoptosis. Leukemia Research, 37, 1271– 1277. Davis, R.E. , Ngo, V.N. , Lenz, G. , Tolar, P., Young, R.M. , Romesser, P.B. , Kohlhammer, H. , Lamy, L. , Zhao, H. , Yang, Y. , Xu, W. , Shaffer, A.L. , Wright, G. , Xiao, W. , Powell, J., Jiang, J.K. , Thomas, C.J., Rosenwald, A. , Ott, G. , MullerHermelink, H.K. , Gascoyne, R.D. , Connors, J.M. , Johnson, N.A. , Rimsza, L.M. , Campo, E. , Jaffe, E.S. , Wilson, W.H. , Delabie, J., Smeland, E.B. , Fisher, R.I. , Braziel, R.M. , Tubbs, R.R. , Cook, J.R. , Weisenburger, D.D. , Chan, W.C. , Pierce, S.K. & Staudt, L.M. (2010) Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature, 463, 88–92. Gauld, S.B. , Dal Porto, J.M. & Cambier, J.C. (2002) B cell antigen receptor signaling: roles in cell development and disease. Science, 296, 1641–1642. Honigberg, L.A. , Smith, A.M., Sirisawad, M. , Verner, E. , Loury, D. , Chang, B. , Li, S. , Pan, Z. , Thamm, D.H. , Miller, R.A. & Buggy, J.J. (2010) The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proceedings of the National Academy of Sciences of the United States of America, 107, 13075–13080. Wang, M.L. , Rule, S. , Martin, P., Goy, A. , Auer, R. , Kahl, B.S., Jurczak, W. , Advani, R.H. , Romaguera, J.E. , Williams, M.E. , Barrientos, J.C. , Chmielowska, E. , Radford, J., Stilgenbauer, S. , Dreyling, M. , Jedrzejczak, W.W. , Johnson, P., Spurgeon, S.E. , Li, L. , Zhang, L. , Newberry, K. , Ou, Z. , Cheng, N. , Fang, B. , McGreivy, J., Clow, F. , Buggy, J.J., Chang, B.Y. , Beaupre, D.M. , Kunkel, L.A. & Blum, K.A. (2013) Targeting BTK with ibrutinib in relapsed or refractory mantlecell lymphoma. New England Journal of Medicine, 369, 507–516.